Rosanna Mendite
Acute Care · Hartford, CTNPI 1295200020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 602 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,502 and has fallen 88.5% since, to $401 in 2025. Among acute care clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 602 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Amgen$907
- Boehringer Ingelheim$804
- Bayer$641
- plus $4K from 28 others
What the payments were for
- Food & beverage$11,31999%
- Education$1481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 138 | $2,083 |
| Lilly USA, LLC | 84 | $1,423 |
| AstraZeneca | 58 | $1,273 |
| Amgen | 39 | $907 |
| Boehringer Ingelheim | 47 | $804 |
| Bayer | 23 | $641 |
| Abbott | 28 | $588 |
| Currax Pharmaceuticals LLC | 35 | $487 |
| Merck | 16 | $312 |
| Amneal Pharmaceuticals LLC | 14 | $292 |
| Cequr Corporation | 3 | $287 |
| Amarin Pharma, Inc. | 19 | $283 |
| Sanofi-aventis U.S. LLC | 12 | $258 |
| AbbVie | 13 | $242 |
| Corcept Therapeutics | 8 | $213 |
| Insulet Corporation | 9 | $201 |
| Xeris Pharmaceuticals, Inc. | 10 | $200 |
| IBSA Pharma Inc. | 9 | $198 |
| Dexcom, Inc. | 7 | $143 |
| Kyowa Kirin, Inc. | 4 | $97 |
| Medtronic | 3 | $68 |
| Mannkind Corporation | 3 | $66 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| Clarus Therapeutics Inc. | 4 | $65 |
| Acella Pharmaceuticals, LLC | 3 | $56 |
| Lifescan, Inc. | 2 | $42 |
| Novartis | 1 | $27 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Radius Health, Inc. | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,467 in reported general payments places this provider in the 95th percentile of 239 acute care providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 31 | $55,752 |
| OzempicSemaglutide | 32 | $54,870 |
| FarxigaDapagliflozin Propanediol | 33 | $37,603 |
| MounjaroTirzepatide | 25 | $30,324 |
| JardianceEmpagliflozin | 21 | $28,024 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $13,052 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $11,905 |
| Armour ThyroidThyroid,pork | 16 | $1,014 |
| Levothyroxine Sodium | 35 | $503 |
| Alendronate Sodium | 15 | $64 |
| Metformin Hcl | 14 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,423 | $86,07656 claims |
| Novo NordiskOzempic | $2,083 | $54,87032 claims |
| AstraZenecaFarxiga | $1,273 | $37,60333 claims |
| Boehringer IngelheimJardiance | $804 | $28,02421 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $258 | $11,90513 claims |
| AbbVieArmour Thyroid | $242 | $1,01416 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $292 | $50335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 acute care providers in Connecticut.
Other acute care in Hartford
- Mary CicchettiHartford$7K
- Daniel MeewesHartford$7K
- Danette GuertinHartford$4K
- Mariam NasiriHartford$4K
- Carolyn TschummiHartford$2K
- Patrick FergusonHartford$2K
- Christina CloutHartford$2K
- Bryan FrankovitchHartford$1K
- Mallory MacdonaldHartford$1K
- Julia MooreHartford$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.